Generated by AI
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology products with an emphasis on photodynamic therapy. Its commercial portfolio centers on Ameluz, a prescription topical gel used together with BF-RhodoLED and RhodoLED lamp systems for the treatment of actinic keratoses, a common precancerous skin condition. The company also markets Xepi, a topical antibiotic for impetigo, expanding its presence in prescription skin care. Biofrontera works directly with dermatology practices and specialist groups, supporting clinical use through products designed for office-based treatment settings. Headquartered in Woburn, Massachusetts, Biofrontera plays a niche role in the dermatology market by combining drug and device-based therapies for targeted skin treatment.
Website660 Main Street
Woburn, MA, 01801
United States
The latest articles about BFRI.
Summary of Nov 13's posts. Generated by AI.
Summary of Sep 14's posts. Generated by AI.
Summary of Oct 31's posts. Generated by AI.
Summary of Sep 15's posts. Generated by AI.
Investors talking about BFRI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.